Peptide Research
GLP-1 Receptor Agonist Peptides: Research Comparison Guide
For research use only. Not for human consumption. LiveWell Peptides supplies research compounds for in-vitro laboratory research only. Nothing on this page is medical advice, a treatment claim or dosing guidance. FDA-approved medicines containing these molecules are prescription products available only through a licensed provider.
Quick answer: Semaglutide, tirzepatide and retatrutide are incretin receptor agonist peptides that differ mainly in how many receptors they target: GLP-1 only, GLP-1 plus GIP, and GLP-1 plus GIP plus glucagon. This guide summarizes their structure, receptor pharmacology and the published clinical literature so researchers can compare them. Research-grade material is sold for laboratory study only.
What Are GLP-1 Receptor Agonist Peptides?
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells. Native GLP-1 is cleared within minutes by the enzyme DPP-4, so synthetic analogs are engineered with amino acid substitutions and fatty acid side chains that extend their half-life to roughly a week. Researchers study these analogs to understand incretin signalling, glucose-dependent insulin secretion, gastric emptying and central appetite pathways.
Three Generations of Incretin Peptides
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1R | GIPR + GLP-1R | GIPR + GLP-1R + GCGR |
| Length | 31 amino acids, acylated | 39 amino acids, acylated | 39 amino acids, acylated |
| Reported half-life | About 7 days | About 5 days | About 6 days |
| Regulatory status | Approved as prescription medicines | Approved as prescription medicines | Investigational, in Phase 3 trials |
| Key published trials | STEP, SUSTAIN, SELECT | SURPASS, SURMOUNT | Phase 2 (NEJM 2023), TRIUMPH |
Receptor Pharmacology
Semaglutide: selective GLP-1R agonist
Semaglutide binds the GLP-1 receptor, a class B G protein-coupled receptor, and signals mainly through Gs and cyclic AMP. Its C18 fatty diacid side chain drives albumin binding, which is the basis for its long half-life in published pharmacokinetic studies.
Tirzepatide: dual GIP and GLP-1 receptor agonist
Tirzepatide is built on the GIP peptide backbone and is imbalanced in favor of the GIP receptor, with lower relative potency at GLP-1R. Published work also reports biased signalling at GLP-1R, favoring cAMP generation over beta-arrestin recruitment, which is an active research question.
Retatrutide: triple GIP, GLP-1 and glucagon receptor agonist
Retatrutide adds glucagon receptor activity. In research models, glucagon receptor signalling is studied for its effects on hepatic lipid handling and energy expenditure, which is why the triple agonist class draws interest in metabolic research.
What the Published Clinical Literature Reports
The figures below summarize primary endpoints from peer-reviewed trials of the approved or investigational medicines. They describe results in supervised clinical trials, not outcomes from research-grade material, and are included for literature comparison only.
- Semaglutide, STEP 1 (68 weeks): mean body weight change of about 14.9 percent versus about 2.4 percent with placebo [2].
- Semaglutide, SELECT: a 20 percent relative reduction in major adverse cardiovascular events in adults with obesity without diabetes [7].
- Tirzepatide, SURMOUNT-1 (72 weeks): mean body weight change of up to about 20.9 percent at the highest dose [5].
- Tirzepatide vs semaglutide, SURPASS-2: greater HbA1c reduction for tirzepatide in type 2 diabetes [4].
- Retatrutide, Phase 2 (48 weeks): mean body weight change of up to about 24.2 percent at the highest dose [6].
Across these trials the most frequently reported adverse events were gastrointestinal. Full safety information for the approved medicines is published by the U.S. Food and Drug Administration.
Active Research Areas
- Cardiovascular outcome signalling [7]
- Hepatic steatosis and liver lipid metabolism
- Renal outcomes
- Central nervous system GLP-1R expression and reward pathways
- Oral delivery formulations and small molecule GLP-1R agonists
- Lean mass composition during incretin receptor agonism
Research-Grade vs Prescription Products
Research-grade peptides are chemical reagents supplied for laboratory study. They are not approved medicines, are not manufactured or labelled for human or veterinary use, and must not be used as a substitute for a prescription product. Researchers should verify identity and purity for every lot using the batch-specific Certificate of Analysis (HPLC and mass spectrometry).
Frequently Asked Questions
What is the difference between semaglutide, tirzepatide and retatrutide?
The number of receptors each one activates. Semaglutide targets the GLP-1 receptor, tirzepatide targets GIP and GLP-1 receptors, and retatrutide targets GIP, GLP-1 and glucagon receptors.
Which of these molecules are approved medicines?
Semaglutide and tirzepatide are active ingredients in FDA-approved prescription medicines. Retatrutide is investigational and not approved.
Are research-grade peptides the same as prescription medicines?
No. Research-grade peptides are laboratory reagents that are not approved for human use. Approved medicines are available only by prescription through a licensed provider.
What documentation should a researcher expect?
A lot-specific Certificate of Analysis showing HPLC purity and mass spectrometry identity, plus storage guidance for the lyophilized material.
Does LiveWell provide dosing or usage guidance?
No. LiveWell supplies compounds for in-vitro laboratory research only and does not provide dosing, administration or medical guidance of any kind.
References
- [1] Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844.
- [2] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
- [3] Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide (SURPASS-1). Lancet. 2021;398:143-155.
- [4] FrÃas JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515.
- [5] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216.
- [6] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389:514-526.
- [7] Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.
For research use only. Not for human consumption. This article summarizes published scientific literature for educational purposes. It is not medical advice and makes no claim about the effect of any LiveWell product.
